Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Screening Metabolic Biomarkers in KRAS Mutated Mouse Acinar and Human Pancreatic Cancer Cells via Single-Cell Mass Spectrometry.

Analytical chemistry - 26 Mar 2024

Liu Qinlei, Lan Jiayi, Martínez-Jarquín Sandra, Ge Wenjie, Zenobi Renato

Abstract excerpt

Pancreatic cancer is a highly aggressive and rapidly progressing disease, often diagnosed in advanced stages due to the absence of early noticeable symptoms. The KRAS mutation is a hallmark of pancreatic cancer, yet the underlying mechanisms driving pancreatic carcinogenesis remain elusive. Cancer cells display significant metabolic heterogeneity, which is relevant to the pathogenesis of cancer. Population...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acinar Cells
Share to Biomarkers
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Early Detection of Cancer

Share to Mass Spectrometry

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 38471062
DOI: 10.1021/acs.analchem.3c05741

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Screening Metabolic Biomarkers in KRAS Mutated Mouse Acinar and Human Pancreatic Cancer Cells via Single-Cell Mass Spectrometry.PMID 38471062Read ↗

Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Metabolomic, Proteomic, and Single-Cell Proteomic Analysis of Cancer Cells Treated with the KRASG12D Inhibitor MRTX1133.Semantic proximity Read ↗

Meta-analysis of targeted metabolomics data from heterogeneous biological samples provides insights into metabolite dynamicsSemantic proximity Read ↗

Integrated spatial transcriptomics and lipidomics of precursor lesions of pancreatic cancer identifies enrichment of long chain sulfatide biosynthesis as an early metabolic alterationSemantic proximity Read ↗

Integrated spatial omics of metabolic reprogramming and the tumor microenvironment in pancreatic cancerSemantic proximity Read ↗

Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modelingSemantic proximity Read ↗

Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modelingSemantic proximity Read ↗

Integration of clinical phenoms and metabolomics facilitates precision medicine for lung cancer.Semantic proximity Read ↗

Evolutionary metabolic landscape from preneoplasia to invasive lung adenocarcinomaSemantic proximity Read ↗

Metabolomics Profiling of EUS-FNA Sample Predicts Advanced Pancreatic Adenocarcinoma PrognosisSemantic proximity Read ↗

Metabolomic, proteomic and single cell proteomic analysis of cancer cells treated with the KRAS <sup>G12D</sup> inhibitor MRTX1133Semantic proximity Read ↗

Harnessing the Power of Metabolomics for Precision Oncology: Current Advances and Future DirectionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.